retatrutide mechanism gip glp-1 glucagon triple agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy retatrutide mechanism of action triple

Mar 24, 2026 Experienced researchers know something about retatrutide sourcing that newcomers learn the hard way

Nephrologists defined their ideal patient as someone with diabetic kidney disease exhibiting persistently elevated urinary albumin-to-creatinine ratio (ACR) or decline in eGFR with proper reninangiotensinaldosterone system (RAAS) blockade, starting with SGLT2is first and subsequently adding GLP1-RAs

Patients with cardiovascular risk factors may therefore find a GLP-1RA more appropriate owing to the improvements in cardiometabolic parameters that have been observed with this drug class [10, 37, 46, 47]

To view or add a comment, sign in Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech by The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial